Avalo Therapeutics annual revenue
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Avalo Therapeutics Revenue Growth & History (AVTX)
Avalo Therapeutics reported $59,000 in revenue for fiscal 2025, a decrease of 86.62% from the previous fiscal year.
View full Avalo Therapeutics company overviewAvalo Therapeutics annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $59,000 | −$382,000 | −86.62% |
| 2024 | 2024-12-31 | $441,000 | −$1.5M | −77.08% |
| 2023 | 2023-12-31 | $1.9M | −$16.1M | −89.34% |
| 2022 | 2022-12-31 | $18.1M | $12.7M | +234.40% |
| 2021 | 2021-12-31 | $5.4M | −$1.3M | −19.42% |
| 2020 | 2020-12-31 | $6.7M | −$51,351 | −0.76% |
| 2019 | 2019-12-31 | $6.8M | −$278,027 | −3.96% |
| 2018 | 2018-12-31 | $7.0M | −$20.8M | −74.73% |
| 2017 | 2017-12-31 | $27.8M | $26.7M | +2312.27% |
| 2016 | 2016-12-31 | $1.2M | $1.2M | — |
| 2015 | 2015-12-31 | $0 | — | — |
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Primary source
SEC company filings
TickerStat standardizes reported company facts from SEC EDGAR. Derived growth rates use the displayed revenue values and are not company guidance or forecasts.
Review Avalo Therapeutics filings at SEC.gov ↗